It could be the overhang of news from St. Jude that medical equipment sales are struggling given uncertainty over health care bill. I sure hope that is a St. Jude issue and not a similar issue at VOLC. I got word from one asset manager who spoke to several cardiologists he has relationships with who were skeptical of IVUS and emphasized that it was time consuming and provided no additional reimbursement. Whether or not they were up-to-date with the FAME and PROSPECT studies is unknown, but clearly, convincing hospitals to purchase new equipment is not easy in this environment. VOLC sales force needs to convince hospitals and cardiologists that the FAME and PROSPECT studies are for real and that they will see the significant cost-benefit. As all doctors, cardiologists want to provide better care, but they also want to get paid to do the IVUS work. Medicare and Insurance companies need to see the benefit and pay extra for the procedures at a rate to entice the increased use of IVUS in order to change the standard of care. VOLC's operating leverage is there IF management can get IVUS procedures to the next level in the global healthcare purchasing and reimbursement process. But, can VOLC and its salespeople make this happen??? Will the hospital budgets still be constrained??? Lots of questions that need answering in this quarter.